Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults. A wide variety of chromosomal abnormalities are associated with CLL, ranging from single nucleotide variants (SNVs) and insertions/deletions (indels) up to large copy number variations (CNVs), including trisomies.
Designed in collaboration with leading cancer experts the enhanced SureSeq™ CLL + CNV V3 Panel enables more expansive genetic profiling of your samples. Our panel allows you to target 16 key disease-associated genes and 5 chromosomal regions implicated in CLL progression, including enhanced TP53 variant detection.
SureSeq CLL + CNV V3 NGS Panel
Technical information
Ordering information
* Exon examples not yet available
We have a regularly updated, expert-curated library of pre-optimized cancer panel content for you to select from. Simply mix and match the gene, exonic or intronic content you need to create a CLL next generation sequencing cancer panel that meets your exact requirements.
Investigating both chromosomal aberrations and SNVs/indels is imperative to advance research into CLL progression and treatment. Cytogenetic abnormalities are present in more than 80% of patients with previously untreated CLL, the most frequent being del(13q), del(11q), del(17p), del(6q) and trisomy 121. Some of these CNVs cover important tumor suppressors, such as del(17p) resulting in the loss of the TP53 gene and del(11q) resulting in loss of ATM. More recently, other genes have also been found to be mutated in CLL, including NOTCH1, SF3B1, MYD88 and BIRC3, adding to the genomic complexity of this leukemia2. Together with leading cancer experts, we continue to monitor the latest CLL research, which is reflected in the latest V3 panel design through enhanced gene coverage for BTK and PLCG2, plus the inclusion of baits for BCL2 and NRAS genes.
Due to this genetic heterogeneity, current analysis strategies for CLL require multiple methods to obtain a comprehensive genetic picture, often using microarray or fluorescence in situ hybridization (FISH) to detect structural abnormalities in combination with NGS for somatic variants. With OGT’s SureSeq CLL + CNV V3 Panel, you can now obtain a more complete understanding of the genetic makeup of CLL progression in each sample using a single assay.
Table 1: The SureSeq CLL + CNV V3 Panel targets the 5 most common chromosomal regions implicated in CLL and 16 genes, plus the SRY gene and 24 SNPs for easy sample tracking.
OGT’s pioneering experience in hybridization-based technology means the SureSeq CLL + CNV V3 Panel provides you with better coverage uniformity, fewer false positives, and superior variant detection. Designed for detection down to 1% variant allele frequency (VAF) in 16 key genes (Figure 1) plus the SRY gene and 24 SNPs, to allow for easy sample tracking3, you can be confident you’re getting the full genetic profile of your sample. Additionally, we have enhanced this panel with the inclusion of reference DNA for baseline CNV calling, to increase your labs efficiency with reduced false positives and lower inter-run variability assuring you of accurate sample characterization.
The SureSeq CLL + CNV V3 Panel covers the 5 most common CNVs in CLL. Compared to array data, often considered the gold standard for CNV detection, the events reported with the SureSeq CLL + CNV V3 Panel were 100% concordant, even in genomic regions containing multiple aberrations (Figures 2 - 3). More so, facilitated by OGT’s excellent bait design, loss-of-heterozygosity (LOH) can be identified and support CNV calls. With a CNV size detection ranging from small CNVs through to complete loss of a chromosomal arm and whole chromosome gains (trisomy 12), your data provides a more comprehensive genetic picture for each sample, all in a single assay.
Figure 1: Illustration of the excellent uniformity and high depth of coverage allowing confident detection of [A] a SF3B1 exon 15 hotspot variant Lys700Glu with 4.8% allele frequency and [B] a TP53 exon 4 frameshift deletion (TP53 c.124del) with frequency 38.9%.
Figure 2: 42.7 Mb deletion of 11q covering ATM.
Figure 3: 0.6 Mb biallelic loss called within a larger ~1 Mb single allele deletion in the region covering DLEU2/DLEU1/DLEU7 on chromosome 13q.
Interpret NGS Analysis Software is OGT’s powerful and easy-to-use data analysis solution, facilitating analysis and visualization of a wide range of somatic variants and structural aberrations. Designed to work seamlessly with all SureSeq panels, Interpret perfectly complements the SureSeq CLL + CNV V3 Panel, delivering fast and accurate detection of all SNVs, indels, LOH and CNVs covered by the panel. Following detection, all events can be readily visualized in the user-friendly variant browser, for an effortless translation of all your CLL data into meaningful results (Figure 4).
Figure 4: Following analysis, all variants and CNVs are visualised for easy interpretation in OGT’s Interpret NGS Analysis Software. In this example a trisomy 12 is detected, showing a reliable gain call across the whole chromosome.
With our NGS customization service you can tailor your panel using OGT’s regularly updated, expert-curated library of pre-optimized cancer content. Add or remove targets to meet your specific analytical needs, ensuring maximum efficiency and focus on the most relevant insights for your research.
Visit International site
Visit USA site
International
